Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study Evaluating HSV-tk + Valacyclovir Gene Therapy in Combination With Androgen Deprivation Therapy, Brachytherapy, External Beam Radiotherapy, and Prostatectomy for High-Risk Prostate Cancer

Trial Profile

Phase II Study Evaluating HSV-tk + Valacyclovir Gene Therapy in Combination With Androgen Deprivation Therapy, Brachytherapy, External Beam Radiotherapy, and Prostatectomy for High-Risk Prostate Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2019

At a glance

  • Drugs Aglatimagene besadenovec (Primary) ; Bicalutamide (Primary) ; Leuprorelin (Primary) ; Valaciclovir (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jan 2019 According to a Candel Therapeutics media release, the company has received the Series B financing from PBM Capital Group, for Active Surveillance of this study.
    • 24 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 24 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top